Antibodies, Proteins, Kits and Reagents for Life Science

247 929 ₸ Product size

100 µl 247 929 ₸

Order now and get it on Wednesday March 10, 2021

Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857)

Key features and details

Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
Rabbit monoclonal [EPR494] to CCL4/MIP-1 beta
Suitable for: IP, ICC/IF, WB
Reacts with: Human, Recombinant fragment

Product name

Anti-CCL4/MIP-1 beta antibody [EPR494]
See all CCL4/MIP-1 beta primary antibodies
Description

Rabbit monoclonal [EPR494] to CCL4/MIP-1 beta
Host species

Rabbit

Tested Applications & Species

Application	Species
ICC/IF	Human
IP	Human
WB	Human Recombinant fragment

See all applications and species data

Immunogen

Synthetic peptide within Human CCL4/MIP-1 beta aa 50 to the C-terminus (C terminal). The exact sequence is proprietary.
Database link: P13236
Positive control
- THP-1 cell lysate
General notes
This product was previously labelled as Macrophage Inflammatory Protein 1 beta, MIP1 beta

This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
For more information see here.
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.

One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.

Learn more here.

Form

Liquid
Storage instructions

Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage buffer

pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, PBS
Concentration information loading...
Purity

Tissue culture supernatant
Clonality

Monoclonal
Clone number

EPR494
Isotype

IgG
Research areas

Western blot - Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857)

All lanes : Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857) at 1/1000 dilution

Lane 1 : Untreated THP-1 (human acute monocytic leukemia) lysate
Lane 2 : THP-1 (human acute monocytic leukemia) treated with 100 nM Phorbol-12-myristate-13-acetate(PMA) overnight, then treated with Lipopolysaccharides (LPS) 100 ng/mL for 7 hours and then 1 µg/mL Brefeldin A was added for the last 3 hours, lysate

Lysates/proteins at 10 µg per lane.

Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

Predicted band size: 10 kDa
Observed band size: 12 kDa
why is the actual band size different from the predicted?

Exposure time: 15 seconds

Blocking/Diluting buffer 5% NFDM /TBST.

CCL4/MIP-1 beta (CCL4) is induced in macrophages following exposure to bacterial LPS (PMID: 9848081).
Immunocytochemistry/ Immunofluorescence - Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857)

Immunocytochemistry/Immunofluorescence analysis of THP-1 (Human monocytic leukemia cell line) labeling CCL4/MIP-1 beta/CCL4 + CCL4L with ab40857 at 1/100. Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor^® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. Cells were counter-stained with ab195889, Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor^® 594) at 1/200. Nuclei were counterstained with DAPI (blue).

The expression increased after treatment with Lipopolysaccharides (LPS), 100 ng/mL for 4 hours, followed by addition of Brefeldin A (1 μg/mL) for 3 hours.
Western blot - Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857)

All lanes : Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857) at 1/10000 dilution

Lane 1 : Untagged human CCL4 recombinant protein (aa24-92)
Lane 2 : Untagged human CCL4L recombinant protein (aa24-92)
Lane 3 : GST-tagged human CCL3 recombinant protein (aa27-92)
Lane 4 : GST-tagged human CCL3L recombinant protein 2*(aa28-93)

Lysates/proteins at 10 µg per lane.

Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

Predicted band size: 10 kDa
Observed band size: 12 kDa why is the actual band size different from the predicted?

Exposure time: 3 seconds

Blocking/Diluting buffer 5% NFDM /TBST
Immunoprecipitation - Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857)

ab40857 at 1/50 immunoprecipitating CCL4/MIP-1 beta/CCL4 + CCL4L in THP-1 (Human monocytic leukemia cell line) whole cell lysate observed at 12 KDa (lanes 1 and 2).

Lane 1 (input): THP-1 treated with 100 nM PMA overnight, then treated with 100 ng/mL LPS for 7 hours and 1 μg/mL Brefeldin A was added for the last 3 hours whole cell lysate, 10μg

Lane 2 (+): ab40857 + THP-1 treated with 100 nM PMA overnight, then treated with 100 ng/mL LPS for 7 hours and 1μg/mL Brefeldin A was added for the last 3 hours whole cell lysate

Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab40857 in THP-1 treated with 100 nM PMA overnight, then treated with 100 ng/mL LPS for 7 hours and 1 μg/mL Brefeldin A was added for the last 3 hours whole cell lysate

For western blotting: ab40857 at 1/1000 followed by ab131366 VeriBlot for IP Detection Reagent (HRP) for detection at 1/000.

Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
Anti-CCL4/MIP-1 beta antibody [EPR494] (ab40857)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com